Platelet transfusion therapy.
Platelet transfusions are of unquestionably proven benefit for the correction of thrombocytopenia or functional platelet disorders, and they have allowed for more intensive antineoplastic therapy. With the advent of blood component therapy most modern blood banks now have the capabilities for supplying at least limited quantities of platelets. Refinements in procurement methods will inevitably lead to a greater supply of platelets and the establishment of larger transfusion programs. These programs will need to incorporate facilities for platelet storage, recruitment of suitable donors, selection of special donors for refractory patients, and methods for quality control. As antineoplastic therapy becomes more aggressive, such transfusion programs will become an integral part of the operation of cancer treatment centers.
D001772:Blood Cell Count; D001791:Blood Platelet Disorders / Q000628:therapy; D001792:Blood Platelets / Q000276:immunology; D001793:Blood Preservation; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000150:complications; D002469:Cell Separation; D005112:Extracorporeal Circulation / Q000009:adverse effects; D005260:Female; D006680:HLA Antigens; D006470:Hemorrhage / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D017713:Platelet Transfusion; D011247:Pregnancy; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*; D013997:Time Factors
D006680:HLA Antigens